[go: up one dir, main page]

MX2020002038A - Métodos para el tratamiento de distrofia muscular. - Google Patents

Métodos para el tratamiento de distrofia muscular.

Info

Publication number
MX2020002038A
MX2020002038A MX2020002038A MX2020002038A MX2020002038A MX 2020002038 A MX2020002038 A MX 2020002038A MX 2020002038 A MX2020002038 A MX 2020002038A MX 2020002038 A MX2020002038 A MX 2020002038A MX 2020002038 A MX2020002038 A MX 2020002038A
Authority
MX
Mexico
Prior art keywords
muscular dystrophy
methods
treating muscular
treating
disclosure provides
Prior art date
Application number
MX2020002038A
Other languages
English (en)
Inventor
Edward M Kaye
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of MX2020002038A publication Critical patent/MX2020002038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

La presente descripción proporciona, entre otras cosas, composiciones y métodos mejorados para tratar la distrofia muscular; por ejemplo, la descripción proporciona métodos para tratar pacientes con distrofia muscular de Duchenne que tienen una mutación en el gen DMD que es susceptible de omisión del exón 53 administrando una cantidad eficaz de golodirsen.
MX2020002038A 2017-08-31 2018-08-31 Métodos para el tratamiento de distrofia muscular. MX2020002038A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762553094P 2017-08-31 2017-08-31
US201762565824P 2017-09-29 2017-09-29
US201862725129P 2018-08-30 2018-08-30
PCT/US2018/049151 WO2019046755A1 (en) 2017-08-31 2018-08-31 METHODS FOR TREATING MUSCLE DYSTROPHY

Publications (1)

Publication Number Publication Date
MX2020002038A true MX2020002038A (es) 2020-09-18

Family

ID=65526062

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002038A MX2020002038A (es) 2017-08-31 2018-08-31 Métodos para el tratamiento de distrofia muscular.

Country Status (15)

Country Link
US (1) US20230038956A1 (es)
EP (1) EP3675836A4 (es)
JP (2) JP2020532504A (es)
KR (1) KR20200046069A (es)
CN (1) CN111417388A (es)
AR (1) AR112538A1 (es)
AU (1) AU2018326780A1 (es)
CA (1) CA3073736A1 (es)
CO (1) CO2020004034A2 (es)
IL (1) IL272791A (es)
MA (1) MA50062A (es)
MX (1) MX2020002038A (es)
SG (1) SG11202001074RA (es)
TW (1) TW201919655A (es)
WO (1) WO2019046755A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
EP4644567A2 (en) 2015-11-30 2025-11-05 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
WO2018017754A1 (en) 2016-07-19 2018-01-25 Duke University Therapeutic applications of cpf1-based genome editing
WO2020257489A1 (en) * 2019-06-19 2020-12-24 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
WO2021257673A2 (en) * 2020-06-17 2021-12-23 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of muscular dystrophy
CN112430645A (zh) * 2020-12-09 2021-03-02 北京华瑞康源生物科技发展有限公司 一种多重实时荧光pcr法检测人dmd基因拷贝数的相对定量方法及试剂盒
EP4486386A1 (en) 2022-03-03 2025-01-08 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
NZ631132A (en) * 2013-03-14 2017-06-30 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
BR112015022998A2 (pt) * 2013-03-15 2017-11-14 Sarepta Therapeutics Inc composições melhoradas para o tratamento de distrofia muscular
BR112018007066A2 (pt) * 2015-10-09 2018-10-23 Sarepta Therapeutics Inc composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados

Also Published As

Publication number Publication date
AR112538A1 (es) 2019-11-06
SG11202001074RA (en) 2020-03-30
CO2020004034A2 (es) 2020-04-24
CA3073736A1 (en) 2019-03-07
WO2019046755A1 (en) 2019-03-07
AU2018326780A1 (en) 2020-02-27
US20230038956A1 (en) 2023-02-09
JP2020532504A (ja) 2020-11-12
CN111417388A (zh) 2020-07-14
TW201919655A (zh) 2019-06-01
EP3675836A1 (en) 2020-07-08
IL272791A (en) 2020-04-30
KR20200046069A (ko) 2020-05-06
JP2023138867A (ja) 2023-10-02
EP3675836A4 (en) 2021-05-26
MA50062A (fr) 2020-07-08

Similar Documents

Publication Publication Date Title
MX2020002038A (es) Métodos para el tratamiento de distrofia muscular.
HK1258823A1 (zh) 用於治疗肌营养不良的方法
MX2021011498A (es) Metodos para tratar la distrofia muscular con casimersin.
NZ631289A (en) Improved compositions for treating muscular dystrophy
PH12019502725A1 (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
WO2019067981A8 (en) Combination therapies for treating muscular dystrophy
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
SA520411910B1 (ar) تركيبات وطرق لعلاج اضطرابات مناعية باستخدام سلالات بكتيرية من المكورات اللبنية المعدلة للمناعة
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MY205512A (en) Arginase inhibitors
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
MX2018003472A (es) Moduladores de la expresion de kras.
EA202192815A1 (ru) Опосредуемая aav-вектором делеция крупной мутационной "горячей точки" для лечения мышечной дистрофии дюшенна
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
MX2021007503A (es) Moduladores de la expresion de hsd17b13.
EP4289822A3 (en) Benzoimidazol-1,2-yl amides as kv7 channel activators
PH12020551995A1 (en) Modulator of apol1 expression
ZA202002936B (en) Phenoxy acids for the treatment of neuromuscular disorders
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
MX2025001486A (es) Composicion que comprende el oligonucleotido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
PH12021551053A1 (en) Modulators of irf5 expression